Back to BBIO Overview
NMS · Valuation Lab
BBIO
BridgeBio Pharma, Inc.
Last$81.99
Market cap16.1B
EV/EBITDA-35.3x
Intrinsic value
$180.24
MoS +54.5% · Undervalued
Assuming 15.0% FCF margin and 60.0% Y1–5 growth.
Upside to price
EV (DCF)36.9B
Terminal share80%
Expected IV$189.50
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 80% of EV
PV of stage FCFs7.5B
PV of terminal value29.3B
Enterprise value36.9B
Net cash / (debt)-1.6B
Equity value35.3B
Intrinsic value / share$180.24
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 927.9M | 139.2M | 128.3M | 92.2% |
| Y2 | 1.5B | 222.7M | 189.3M | 85.0% |
| Y3 | 2.4B | 356.3M | 279.2M | 78.4% |
| Y4 | 3.8B | 570.1M | 411.8M | 72.2% |
| Y5 | 6.1B | 912.2M | 607.5M | 66.6% |
| Y6 | 8.1B | 1.2B | 747.1M | 61.4% |
| Y7 | 10.8B | 1.6B | 918.8M | 56.6% |
| Y8 | 14.4B | 2.2B | 1.1B | 52.2% |
| Y9 | 19.3B | 2.9B | 1.4B | 48.1% |
| Y10 | 25.7B | 3.9B | 1.7B | 44.4% |
| Terminal | — | — | 29.3B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.